The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 696 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.
Questions Answered in This Report:
How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
Which are the top 10 biosimilars developers by number of clinical stage candidates?
When is the expected launch date for late stage pipeline candidates in the seven major markets?
What is the level of competition expected for a brand, globally and by region/country?
Scope:
Markets covered: Global
Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.
Biosimilars Development Pipeline by Phase of Development
Biosimilars Development Pipeline by Class
Biosimilars Development Projects by Reference Molecule
Top 10 Biosimilars Development Projects by Reference Molecule
Leading Biosimilars Developers
Top Biosimilars Developers by Number of Clinical-Stage Biosimilars in the Major Markets
Top Biosimilars Developers by Number of Clinical-Stage Biosimilars, Excluding the Major Markets
Timeline of Expected Biosimilar Launch Dates in the United States
Timeline of Expected Biosimilar Launch Dates in the EU
Timeline of Expected Biosimilar Launch Dates in Japan
Appendix
Methodology
Terminology in Biosimilar Pipeline
Rashi Tiwari
Rashi Tiwari, Pharm.D., Associate Healthcare Research and Data Analyst, Biosimilars. Prior to joining Clarivate, Dr. Tiwari was a research associate in competitive intelligence at Vyuhgenics. She earned her doctorate in pharmacy from KLE College of Pharmacy in Belagavi, where she also interned as a clinical research coordinator at KLE’s Dr. Prabhakar Kore Hospital.
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.